Mirum says LIVMARLI met primary endpoint in Phase 3 EXPAND study
Mirum Pharmaceuticals announced that LIVMARLI (maralixibat) met the primary endpoint in the Phase 3 EXPAND study of ultra-rare cholestatic liver diseases.
Mirum Pharmaceuticals announced that LIVMARLI (maralixibat) met the primary endpoint in the Phase 3 EXPAND study of ultra-rare cholestatic liver diseases.